Bennett JM - Search Results

1

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A; MDS-003 Study Investigators. List AF, et al. Among authors: bennett jm. Leukemia. 2014 May;28(5):1033-40. doi: 10.1038/leu.2013.305. Epub 2013 Oct 22. Leukemia. 2014. PMID: 24150217 Free PMC article.

2

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).

Sekeres MA, Swern AS, Fenaux P, Greenberg PL, Sanz GF, Bennett JM, Dreyfus F, List AF, Li JS, Sugrue MM. Sekeres MA, et al. Among authors: bennett jm. Blood Cancer J. 2014 Aug 29;4(8):e242. doi: 10.1038/bcj.2014.62. Blood Cancer J. 2014. PMID: 25171203 Free PMC article. No abstract available.

3

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A. List AF, et al. Among authors: bennett jm. Leukemia. 2015 Dec;29(12):2452. doi: 10.1038/leu.2015.312. Leukemia. 2015. PMID: 26648407 Free PMC article. No abstract available.

4

Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.

Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH; Eastern Cooperative Oncology Group. Paietta E, et al. Among authors: bennett jm. Leukemia. 2003 Aug;17(8):1544-50. doi: 10.1038/sj.leu.2402999. Leukemia. 2003. PMID: 12886241

5

Monosomal karyotype in MDS: explaining the poor prognosis?

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Schanz J, et al. Among authors: bennett jm. Leukemia. 2013 Oct;27(10):1988-95. doi: 10.1038/leu.2013.187. Epub 2013 Jun 21. Leukemia. 2013. PMID: 23787396 Free article.

6

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group. Larson RA, et al. Among authors: bennett jm. Leukemia. 2002 Sep;16(9):1627-36. doi: 10.1038/sj.leu.2402677. Leukemia. 2002. PMID: 12200674 Clinical Trial.

7

The second international congress on myeloproliferative and myelodysplastic syndromes.

Silver RT, Bennett JM, Deininger M, Feldman E, Rafii S, Silverstein RL, Solberg LA, Spivak JL. Silver RT, et al. Among authors: bennett jm. Leuk Res. 2004 Sep;28(9):979-85. doi: 10.1016/j.leukres.2004.01.012. Leuk Res. 2004. PMID: 15234576

8

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M. Della Porta MG, et al. Among authors: bennett jm. Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27. Leukemia. 2015. PMID: 25721895

9

The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.

Larson RA, Day RS, Azarnia N, Bennett JM, Browman G, Goldberg J, Gottlieb A, Grunwald H, Miller K, Raza A, et al. Larson RA, et al. Among authors: bennett jm. Br J Haematol. 1992 Oct;82(2):337-46. doi: 10.1111/j.1365-2141.1992.tb06427.x. Br J Haematol. 1992. PMID: 1419816 Clinical Trial.

10

Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004.

Fenaux P, Bennett JM, Bowen DT, Knight RD, List AF. Fenaux P, et al. Among authors: bennett jm. Transfus Med. 2007 Jun;17(3):151-60. doi: 10.1111/j.1365-3148.2006.00681.x. Transfus Med. 2007. PMID: 17561855

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

718 results

Search Page

Filters